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Objective: To develop and validate a prognostic model for leflunomide discontinuation 
with abnormal blood-test results. 
Methods: Data from CPRD Gold and Aurum were used for model development and 
external validation respectively. Participants prescribed leflunomide between 
01/01/2007 and 31/12/2019 were followed-up from six-months after first GP-
prescription to the earliest of date of outcome, death, 5-year follow-up or 31/12/2019. 
Candidate prognostic factors were ascertained using theory and data driven 
approaches. Penalised Cox regression was performed to develop the risk equation, 
followed by internal validation using 500-bootstraps to correct for optimism. Multiple 
imputation was applied to handle missing data. Model performance was assessed in 
terms of calibration and discrimination.
Results: Data for 1,487 and 2,329 participants contributing 3,140 and 5,246 person-
years follow-up were included in the development and validation cohorts, respectively. 
Thirteen candidate predictors were included in the model. Epilepsy, and either 
cytopenia or elevated liver enzymes during first six months of shared-care leflunomide 
prescription were strong predictors of drug discontinuation with hazard ratio (95%CI) 
4.39 (1.74 -11.06) and 3.06 (2.15 - 4.35), respectively. The unadjusted and optimism 
adjusted calibration slope in development data was 1.00 (95% CI 0.75-1.25) and 0.72 
(95% CI 0.47-0.97), respectively. The calibration slope in validation data was 0.91 
(95% CI 0.74-1.07).  The model showed prognostic separation with optimism adjusted 
Royston D statistic of 0.73 (95% CI 0.44-1.02).  
Conclusion: We have developed and externally validated an easy-to-use prognostic 
model that may be used to risk-stratify monitoring for leflunomide toxicity and to make 
informed choices about risks when choosing treatments.









































































leflunomide, rheumatoid arthritis, psoriatic arthritis, drug toxicity, monitoring
Rheumatology key messages
• One in five patients established on long-term leflunomide discontinue treatment 
with abnormal monitoring blood-tests.
• This is the first prognostic model to discriminate patients at varying risk of 
leflunomide toxicity.
• The developed tool may be used to risk-stratify monitoring after successful 
stabilisation on leflunomide. 









































































Leflunomide is used in the treatment of inflammatory arthritis when low-dose weekly 
methotrexate is either contraindicated, ineffective, or causes side-effects (1). Although 
head-to-head trials suggest comparable efficacy to methotrexate ≤15 mg/week, 
leflunomide is less well tolerated, with a higher risk of treatment discontinuation, mainly 
due to cytopenia and elevated liver enzymes (2-5). For instance, up to 7.1% patients 
commenced on leflunomide discontinued it by 12 months due to elevated liver 
enzymes in clinical trials (2, 4). Real world data indicates that 9.3% and 20.5% patients 
initiated on long-term leflunomide discontinue treatment with abnormal blood test 
results by 1-year and 5-years, respectively (5). 
The risk factors for target-organ damage from leflunomide are not well understood. In 
the absence of this information, those prescribed long-term leflunomide undergo 
monitoring blood tests every three months (6, 7). This strategy of routine periodic 
testing may not be necessary for those at low risk. Additionally, better understanding 
of predictors for target organ damage will aid patients and rheumatologists when 
choosing disease modifying anti-rheumatic drugs (DMARDs). Thus, the aim of this 
study was to develop and externally validate a prognostic model for leflunomide 
discontinuation due to abnormal monitoring blood-tests at 5-years. 










































































Data from Clinical Practice Research Datalink (CPRD) Gold and Aurum were used for 
model development and external validation respectively (8, 9). 
CPRD is an anonymised longitudinal database of electronic health records, and its’ 
participants are representative of the UK population in terms of age, sex, and ethnicity 
(8). It includes information on demographic details, lifestyle factors (e.g., smoking, 
alcohol intake), diagnoses, results of investigations including blood tests, and details 
of general practitioner (GP) prescriptions during clinical care. 
CPRD Gold and Aurum complement each other in terms of nationwide coverage of 
general practice surgeries. The former uses Vision software while the latter uses 
EMIS. Some general practice surgeries have contributed data to both CPRD Gold and 
Aurum databases. Data from such surgeries were excluded from the validation cohort 
using a bridging file provided by the CPRD to allow for true independent external 
validation.  
Approvals
Ethical approval was obtained from the Independent Scientific Advisory Committee 
(ISAC) of the Medicines and Healthcare Products Regulatory Agency (Reference: 
19_275R).  
Study design
This was a cohort study. Study period was 1st January 2007 to 31st December 2019.
Study population comprised those who received first shared-care leflunomide 
prescription from GP in study period. 
In the UK, DMARDs are initiated in hospital rheumatology clinic and prescriptions are 
initially issued by the rheumatologist until a stable, effective, and well tolerated dose 








































































is reached. During this period, the rheumatology team oversees monitoring blood-
tests. Once the patient is established on treatment, the responsibility for prescribing 
and monitoring is handed to the patients’ GP under a shared-care protocol endorsed 
by the British Society for Rheumatology (BSR) and the Royal College of General 
Practitioners (6). The GP consults with the rheumatologist if there are abnormal blood-
test results or any side-effects, and changes in treatments are directed by the 
rheumatologist. 
Inclusion and exclusion criteria
Participants with autoimmune rheumatic disease (AIRD, e.g.  rheumatoid arthritis, 
axial spondyloarthritis etc.), age ≥ 18 years, with ≥ 12-month follow-up in CPRD Gold 
(Aurum for validation) prior to first ever prescription of leflunomide were eligible (5). 
Exclusion criteria comprised of chronic liver disease, haematological malignancy, 
myelodysplasia, haemolytic anaemia, neutropenia, idiopathic thrombocytopenic 
purpura, or chronic kidney disease (CKD) stage ≥4 as detailed previously (5). 
Outcome
Drug discontinuation with abnormal blood-test result, defined as a prescription gap of 
≥ 90 days, with abnormal blood-test result (or diagnostic code indicating abnormal 
blood-test result) within ±60 days of the last prescription (5). See the Supplementary 
Methods (available at Rheumatology online) for thresholds used to define abnormal 
blood-test results.
Start of follow-up: Participants were followed-up from 180 days after the first 
leflunomide prescription issued by the GP until the earliest of date of outcome, death, 
transfer out of the practice, date of last data collection from the practice, 5-years or 
31/12/2019. 
Predictors








































































Predictors were ascertained using theory and data driven approaches.   
(A) Theory driven: Clinical members of the team comprising a hepatologist, 
nephrologist, haematologist, rheumatologist, gastroenterologist, and GP suggested 
potential predictors. These were supplemented with drugs that increase the risk of 
leflunomide toxicity according to the British National Formulary (BNF). 
(a) Demographic or lifestyle factors. Age, sex, body mass index (BMI), and alcohol 
intake were included as they increase the risk of drug induced liver injury (DILI) 
and smoking was included as it increases the clearance of leflunomide (10, 11). 
(b) Drugs that increase the risk of leflunomide toxicity as per BNF, specifically 
statins, paracetamol, methotrexate, 5-acetyl salicylates, carbamazepine, and 
sodium valproate.
(c) Comorbidities. Diabetes was included as it increases the risk of DILI (10).
(d) Cytopenia (neutrophil count <2 x 109/l, total leucocyte count <4 x 109/l, or 
platelet count <150 109/l,) or liver enzyme elevation (ALT/AST levels >35 IU/l) 
during the first six months of shared-care leflunomide prescription were 
included. This is because blood-test abnormalities predict cytopenia and/or 
transaminitis due to other DMARDs (12, 13). 
The latest record of demographic and lifestyle factors prior to start of follow-up, 
diagnostic code for comorbidities in the 2-years prior to start of follow-up, and 
prescription and blood-test results in the six-month prior to start of follow-up were used 
to define the prognostic factors. A longer look-back was used to capture data on 
comorbidities as GPs usually review patients with chronic illnesses annually.  
(B) Data driven: All diagnoses for study participants within 2-years of start of follow-up 
were extracted and classified into chronic disease categories. Hypothesis-free logistic 
regression adjusted for age and gender was undertaken to identify potential prognostic 








































































factors that associate with outcome of interest. Potential risk factors associated with 
outcome with p < 0.10 and present in >=1% of the derivation cohort were included in 
the prognostic model. Uncommon prognostic factors were excluded to avoid model 
imbalance.  
Sample size
To minimise model overfitting and ensure precise estimation of overall risk, the 
minimum sample size required for new model development is 1398 participants (189 
events) based on a maximum of 20 parameters, Cox-Snell R2 value of 0.12, estimated 
event rate of 0.057/person-year, a 5-year time horizon, and a mean follow-up period 
of 2.36 years using the findings from our earlier work (5). (See Supplementary 
Methods, available at Rheumatology online, for Stata syntax) 
Statistical analysis
Mean (standard deviation (SD)) and n (%) were used for descriptive purposes. We 
applied multiple imputation to handle missing values using chained equations. We 
carried out 10 imputations in the development dataset as there tends to be no 
additional benefit for using more than 5-10 imputations (14). We used five imputations 
for the validation data - a pragmatic approach considering the large size of CPRD 
Aurum. The imputation model included all candidate predictors, Nelson-Aalen 
cumulative hazard function and outcome variables. 
Model development
All candidate predictors were included in the Cox model and coefficients of each 
predictor estimated and combined using Rubin’s rule across the imputed datasets. We 
formed the risk equation for predicting an individual’s risk of leflunomide 
discontinuation due to abnormal blood-test results at 5-years follow-up, using the 
developed model’s baseline survival function at t=5 years, a non-parametric estimate 








































































of survival function when all predictor values are set to zero, which is equivalent to the 
Kaplan-Meier product-limit estimate, along with the estimated regression coefficients 
(β) and the individual’s predictor values (X). This process ultimately led to an equation 
for the predicted absolute risk over time (15): 
Predicted event risk at 5-years =1 – S0(t=5)exp(Xβ)  where S0(t=5) is the baseline survival 
function at 5-years of follow-up and βX is the linear predictor, β1x1+ β2x2+ … + βpxp. 
Regression coefficients (β) are estimated from the developed model. 
Model validation
We assessed the performance of the model in terms of calibration (where 1.00 is the 
ideal) by plotting agreement between predicted and observed events. We performed 
internal validation to correct calibration for optimism (overfitting) by bootstrapping with 
replacement 500 samples of the development data in each imputed dataset. We fitted 
the full model in each bootstrap sample to quantify performance in bootstrap sample 
(apparent performance) and applied the same model to the original sample to test 
model performance and optimism (difference in test performance and apparent 
performance). Uniform shrinkage factor was then estimated as the average of 
calibration slopes from each of the bootstrap samples. This process was repeated in 
each imputed dataset, and the final uniform shrinkage calculated by averaging across 
the estimated shrinkage estimates from all imputations. To account for overfitting 
during model development process, the original β coefficients were penalised by the 
final uniform shrinkage factor and the baseline hazard re-estimated on the basis of the 
shrunken β coefficients to ensure that overall calibration was maintained, producing a 
final model. We calculated the D statistic, a measure of discrimination, interpreted as 
a log hazard ratio (HR), the exponential of which gives the HR comparing two groups 
defined by above/below the median of the linear predictor, and plotted Kaplan-Meier 








































































curves in risk groups to visually assess separation. The cut-points are the 16th, 50th 
and 84th centiles of the linear predictor (mean +/- 1 SD) as determined by Cox’s 
method (16, 17).
External validation of the model
Independent external validation of the final model was performed using data from 
CPRD Aurum within the same start and end of follow-up periods. General practice 
surgeries that also contributed data to CRPD Gold were excluded from the validation 
cohort. The final developed model equation was applied to each individual in the 
validation dataset, and then we examined calibration and discrimination as described 
above. In addition, we examined calibration at 5 years by plotting agreement between 
predicted risk and observed event rate.  
We used Stata-MP version 16 for all statistical analyses. This study was reported in 
line with the transparent reporting of a multivariate prediction model for individual 
prediction or diagnosis (TRIPOD) guidelines (18).










































































Data for 1,487 and 2,329 participants contributing 3,140 and 5,246 person-years 
follow-up were included in the development and validation cohorts, respectively (Table 
1; Supplementary Figures S2 and S3, available at Rheumatology online). The majority 
of participants in both cohorts had rheumatoid arthritis, were female and the cohorts 
had similar prevalence of lifestyle factors, comorbidities and drug treatments. 
On data-driven analyses in the derivation cohort, epilepsy, CKD and nutritional 
intolerances were associated with the outcome of interest with p <0.10 
(Supplementary Table S1, available at Rheumatology online). As nutritional 
intolerances were only present in 0.15% of the derivation cohort, it was not taken 
forward as a candidate predictor. A diagnosis of epilepsy and prescription of sodium 
valproate or carbamazepine was merged together to create a single candidate 
predictor epilepsy to avoid multicollinearity. We used fraction polynomials to model 
non-linear risk relationships with continuous predictors (BMI and age) but these were 
found not to be better than the linear terms, hence BMI and age were not transformed 
(data not shown). Thirteen candidate predictors (17 predictor parameters) were 
selected to be included in the model (Table 2). 
Model development and identification of candidate predictors
In the development dataset, 136 outcome events occurred during the follow-up period 
at a rate (95% CI) of 43.32 (36.62 - 51.25) per 1,000 person-years. Epilepsy, and 
presence of cytopenia or elevated liver enzymes during the first six months of shared-
care leflunomide prescription were strong predictors of leflunomide discontinuation 
with adjusted hazard ratio (95%CI) 4.39 (1.74 -11.06) and 3.06 (2.15 - 4.35) 
respectively (Table 2). 








































































Apparent and internal validation performance statistics
As expected, the calibration slope in the development data was 1.00 (95% CI 0.75-
1.25). From the bootstrap a uniform shrinkage factor of 0.73 was obtained and used 
to shrink predictor coefficients in the final model for optimism (Table 3), and after re-
estimation the final model’s S0(5) was 0.914. 
Royston D statistic was 1.06 (95% CI 0.77 – 1.35), corresponding to HR (95% CI) 2.89 
(2.16-3.86) comparing the risk group above the median of linear predictor to that below 
the median. The optimism adjusted Royston D statistic was 0.73 (95% CI 0.44-1.02) 
corresponding to HR (95% CI) 2.08 (1.55-2.77).   
External validation
In the CPRD Aurum cohort, there were 260 outcome events at a rate (95% CI) of 49.94 
(44.25-56.37) per 1000 person-years.  Application of our final prognostic model to the 
independent population from CPRD Aurum yielded excellent calibration, with a 
calibration slope (95% CI) of 0.91 (0.74-1.07) (Figure 1). The Royston D statistic in the 
validation data was 0.97 (95% CI 0.89 -1.05), corresponding to HR (95% CI) 2.64 (2.44 
-2.86) which suggests that our prediction model provided similar prognostic separation 
to the development dataset. Model discrimination in the derivation and validation data 
was broadly similar but the model seemed less able to distinguish between the lowest 
two risk groups, particularly in the validation data (Figures 2). The observed (and 
predicted) 5-year survival probabilities in validation data in these four risk groups were 
similar: 0.87 (0.90), 0.84 (0.87), 0.73 (0.79), 0.56 (0.59) respectively.
Worked examples
A prognostic score to predict the absolute risk of leflunomide discontinuation after six 
months of primary care prescription and within the next 5-years may be calculated 
using the risk-equation (Figure 3, Supplementary Figure S1, available at 








































































Rheumatology online). Participants with 16th centile and median linear predictor scores 
had 10.8% and 15.7% absolute risk of outcome event respectively over the 5-year 
follow-up period in the development datasets. The corresponding values were 10.9% 
and 15.3% in the validation dataset. 









































































This is the first study to develop and validate a prognostic model that predicts 
leflunomide discontinuation due to target organ damage. It includes routinely collected 
data and provides a readily applicable means of risk stratification. It has excellent 
calibration and good discrimination between higher and lower risk groups. It focussed 
on patients successfully initiated on leflunomide and treated for >6 months as this 
includes majority of burden of monitoring. Current guidelines recommend three-
monthly blood-test monitoring during long-term leflunomide treatment and more 
frequent monitoring in context of polypharmacy or comorbidities (6, 7). However, with 
the exception of concurrent methotrexate prescription, these factors are poorly 
understood (19). Utilising the results from this study, patients at high-risk of 
leflunomide toxicity may be offered more careful monitoring or alternate treatments, 
while those at very-low risk may undergo less frequent monitoring e.g. six-monthly 
testing. Additionally, this study reports that cytopenia and elevated liver enzymes 
including those not sufficiently severe to withdraw treatment within first six-months of 
shared-care GP prescription strongly predict target-organ drug-toxicity. This is a novel 
finding for leflunomide and is consistent with previous observations regarding 
methotrexate (12, 13). Similarly, epilepsy and/or treatment with carbamazepine and 
sodium valproate was a strong predictors of target-organ drug toxicity. These data 
may help inform drug choice in these patients. Statins and paracetamol were also 
strong prognostic factors while other DMARDs such as methotrexate and 5-ASA were 
weak prognostic factors. We did not observe a statistically significant association 
between demographic and lifestyle factors including alcohol excess, and AIRD type 
and outcomes of interest. There is week evidence that alcohol consumption may be a 
risk factors for DILI due to specific drugs such as methotrexate, but not with other 








































































drugs (20). Alcohol use in the preceding 12 months was a negative predictor of severe 
DILI in general (OR (95%CI) 0.33 (0.15–0.76) in a previous study(20). These findings 
should be interpreted with caution as our study was not powered to detect these 
associations. 
Overall, the prognostic model performed well in the external validation dataset with 
excellent calibration. It had low discriminant ability for those at very-low and low 
predicted risk. This is unsurprising as the absolute difference in risk over a 5-year 
horizon between these two groups was only 5%. Reassuringly, our model 
discriminated between low and high-risk subsets which it could be argued is important 
for clinical application. In future, discrimination may be improved by including variants 
associated with leflunomide transaminitis (e.g. C163A in CYP1A2 gene; and 
rs4244285 and rs12248560 in CYP2C19 gene); reduced leflunomide metabolism (e.g. 
rs3213422 in dihydroorotate dehydrogenase gene) and excretion (rs2231137 in 
ABCG2 gene, also linked with gout) (21-26).
Not all prognostic models change practice. To facilitate this, evidence from this study 
will be disseminated to the BSR DMARD monitoring guideline writing group and the 
monitoring strategy will be changed if the BSR recommendations are modified in light 
of the findings. The risk calculators will be available online and included in the in-
practice software used by GPs.
Strengths of this study include adequate power, use of time to event methods, external 
validation in an independent dataset, and the inclusion of prognostic factors that are 
simple to obtain during routine care, and at no additional cost. We followed TRIPOD 
guidelines and used robust statistical methodology to develop and evaluate the 
prognostic model. The study included internal correction for optimism and missing data 
was estimated by multiple imputations. Generalisability of the model was enhanced by 








































































the use of a database with nationwide coverage. We used an exhaustive list of 
potential predictors using data driven and theory driven approaches. 
However, there are several limitations of this study. Firstly, dose reduction due to 
abnormal blood test results was not used to define the outcome as  30% of data on 
leflunomide dose is missing in the CPRD making it difficult to ascertain dose 
reductions (5). Some outcomes may have been related to toxicity to other drugs. 
These two factors may have reduced our model’s performance due to misclassification 
bias. Secondly, it is possible that some outcome events may actually be due to a 
combination of lack of efficacy of leflunomide and a concurrent illness resulting in 
blood test abnormality. However, our validation exercise revealed that 95% of outcome 
events were not explained by a concurrent illness (5). Patients prescribed leflunomide 
from rheumatology clinic were excluded from the study. However, this is unlikely to 
affect the generalisability of our findings as vast majority of long-term prescriptions in 
the UK are issued from primary-care under shared-care prescribing and monitoring 
agreement. Our development dataset had a high shrinkage factor indicating a degree 
of overfitting. 
In conclusion, we have developed and validated a risk prediction equation to quantify 
the absolute risk of leflunomide discontinuation due to abnormal monitoring blood-test 
results over 5-years. We ascertained several strong risk factors that may be useful 
when choosing between DMARDs. Further research is warranted to validate the model 
in other populations and to evaluate the clinical outcomes using this model.
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Data availability: This study used data from the Clinical Practice Research Datalink 
(CPRD). Due to the CPRD data sharing policy, we unable to share this study’s data. 
However, access to CPRD data can be directly requested from the CPRD. 
Patient and Public Involvement (PPI): The study question was discussed at a PPI 
meeting in Nottingham and received support from all present. Study results were 
reported to PPI group and modes of dissemination of study findings were also 
discussed and agreed with them. 















































































Age, mean (SD) year 57 (13) 57 (13)
Female sex 979 (65.8) 1,580 (67.8)
BMI
<18.5 kg/m2 28 (1.9) 28(1.2)
18.5-24.9 kg/m2 426 (28.7) 651 (28.0)
25.0-29.9 kg/m2 470 (31.6) 728 (31.3)
≥30 kg/m2 495 (33.3) 821(35.3)
Missing 68 (4.6) 101(4.3)
Current smoker 
No 1,168 (78.6) 1,878 (80.6)
Yes 319 (21.5) 451 (19.4)
Alcohol use 
Non-user 329 (22.1) 519 (22.3)
Low (1-14 units/week) 805 (54.1) 931 (40.0)
Moderate (15-21 units/week) 43 (2.9) 109 (4.7)
Hazardous (>21 units/week) 76 (5.1) 112 (4.8)
Ex-user 88 (5.9) 354 (15.2)
Missing 146 (9.8) 304 (13.1)
Autoimmune rheumatic disease
Rheumatoid Arthritis 970 (65.2) 1,518 (65.2)
Polymyalgia rheumatica/giant cell arteritis 91 (6.1) 201 (8.6)
Spondyloarthritis 426 (28.7) 610 (26.2)
Comorbidities 
Epilepsy or prescribed carbamazepine or 
valproate  
19 (1.3) 26 (1.1)
Diabetes 149 (10.2) 278 (11.9)
Chronic kidney disease 74 (5.0) 57 (2.5)
Other DMARDs
Methotrexate or 5-aminosalicylates 467 (31.4) 758 (32.6)
Other drugs 
Statins 341 (22.9) 531 (22.8)
Paracetamol 287 (19.3) 464 (19.92)
Blood-test abnormalities
Mild cytopenia or liver enzyme elevation in 
six-months preceding start of follow-up
325 (21.9) 514 (22.1)
1Values are numbers (percentage) unless stated otherwise.  DMARDS: Disease modifying anti-
rheumatic drugs, SD: Standard deviation, CPRD: Clinical Practice Research Datalink. 












































































Age 1.01 (0.99 to 1.03) 0.0094981
Female sex 1.24 (0.83 to 1.83) 0.2128283
Body mass index (kg/m2) 0.98 (0.95 to 1.01) -0.0171081
Smoking status 
Non-smoker/not recorded/ex-smoker Reference -
Current smoker 0.90 (0.57 to 1.42) -0.1056694
Alcohol consumption
Non-drinker Reference -
Low (1-14 units/week) 0.96 (0.63 to 1.46) -0.0400223
Moderate (15-21 units/week) 0.86 (0.26 to 2.86) -0.1474903
Hazardous (>21 units/week) 1.12 (0.47 to 2.69) 0.1171966
Ex-drinker 0.84 (0.37 to 1.87) -0.1774794
AIRD type 
Rheumatoid arthritis Reference -
PMR or GCA 1.03 (0.46 to 2.30) 0.026971
Spondyloarthritis 1.14 (0.76 to 1.70) 0.1266522
Comorbidities 
Epilepsy1 4.39 (1.74 to 11.06) 1.479007
Diabetes 0.88 (0.48 to 1.60) -0.1311263
Chronic Kidney Disease 1.72 (0.96 to 3.06) 0.5400153
Other DMARDs
Methotrexate or 5-aminosalicylates 0.93 (0.64 to 1.35) -0.0733462
Other drugs 
Statins 1.44 (0.94 to 2.22) 0.3666838
Paracetamol 1.45 (0.98 to 2.16) 0.3747208
Blood-test abnormalities
Mild cytopenia or liver enzyme 
elevation in six-months preceding 
start of follow-up
3.06 (2.15 to 4.35) 1.117226
1includes participants prescribed carbamazepine or valproate without a Read code for epilepsy.  
HR: hazard ratio, CI: confidence interval, PMR: polymyalgia rheumatica, GCA : Giant cell arteritis







































¶ Results from a single imputed dataset but similar across the other imputations (data not shown). 
*Refers to performance (95% CI) estimated directly from the data that was used to develop the model.
§ Determined by executing full model in each bootstrap sample (500 samples with replacement), 
calculating bootstrap performance, and applying same model in original sample. 
¥ Average difference between model performance in bootstrap data and test performance in original 
dataset
†subtracting average optimism from apparent performance.   
 CPRD: Clinical Practice Research Datalink 








































































Risk score = 1 – 0.918e(Xβ), where Xβ= 0.0094981*Age in years at first primary-care 
prescription  + 0.2128283 *female-sex - 0.0171081 *BMI - 0.0400223*low alcohol 
intake - 0.1474903*moderate alcohol intake + 0.1171966*hazardous alcohol intake 
- 0.1774794*ex-alcohol intake  - 0.1056694*current smoker - 0.1311263 *diabetes 
+  0.5400153*CKD + 0.026971*GCA/PMR + 0.1266522* Axial spondyloarthritis - 
0.0733462*other-DMARDs + 0.3666838*statins +  0.3747208*paracetamol +  
1.479007*epilepsy or carbamazepine or valproate + 1.117226 *mild cytopenia or 
liver enzyme elevation within six months of primary care LEF prescription. 
All variables are code 0, and 1 if absent or present respectively, except for BMI and 
age that were continuous variables. 0.914 is the baseline survival function at 5-years 
and the other numbers are the estimated regression coefficients for the predictors, 
which indicate their mutually adjusted relative contribution to the outcome risk. 
Figure 3: Equation to predict the risk of leflunomide discontinuation after 6 months of 
primary care prescription and within the next 5-years.









































































Figure 1: Calibration plot in the validation dataset. C-slope of 0.91 (0.74-1.07)
Figure 2: Kaplan-Meier survival estimates in the model development and validation 
datasets.
Figure 3: Equation to predict the risk of leflunomide discontinuation after 6 months of 
primary care prescription and within the next 5-years.
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Figure 1: Calibration plot in the validation dataset. C-slope of 0.91 (0.74-1.07) 
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Figure 2: Kaplan-Meier survival estimates in the model development and validation datasets. 
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